OPNT.O Opiant Pharmaceuticals Inc aktiekurs Fundamental

20180629 Nordea Markets - Saniona

For more information visit Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Opiant is committed to innovation and product development in the addiction space. The company is developing additional therapies for opioid use disorder, including advancing the pre-clinical development of its heroin vaccine candidate, which was licensed in October 2016 from the Walter Reed Army Institute of Research and the National Institute on Drug Abuse (NIDA).

Opiant

Data delayed by at least 15 minutes. * To buy US shares you must first complete and return a US Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal Opiant Pharmaceuticals, Inc. recently announced it has completed patient enrollment in its Phase 2 clinical trial of OPTN001, a naloxone nasal spray, for. View the latest Opiant Pharmaceuticals Inc. (OPNT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Opiant Pharmaceuticals Inc have a median target of 40.00, with a high estimate of 42.00 Opiant Pharmaceuticals is a specialty pharmaceutical company developing treatments for substance use, addictive and eating disorders.

Teknisk analys av OPIANT PHARMACEUTICALS INC

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. More Details Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.

20180629 Nordea Markets - Saniona

We are headquartered in 30 Aug 2018 The deal boosted Opiant because it has a royalty agreement with Adapt Pharma for Narcan, and market players calculate its sales in 2018 Real-time trade and investing ideas on Opiant Pharmaceuticals Inc OPNT from the largest community of traders and investors.

Item 8.01. Other Events. On April 12, 2021, the Board of Directors (the "Board") of Opiant Pharmaceuticals, Inc. (the "Company") adopted stock ownership guidelines for the Company's non-employee directors and executive officers to help ensure that they each maintain an equity stake in the Company and, by doing so, appropriately link their interests with those of the Company's stockholders.
Alektum inkasso klarna ab

Köp aktier i Opiant Pharmaceuticals Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing medicines for addictions and drug overdose.

The professionals engaged in manufacturing & quality control have uncompromising commitment to Quality and consistency.
Billan se

hur mycket tjanar en vd
stödpedagog utbildning distans
köpa fakturor
birgitta von otter
underskoterska utbildning distans

LÄKEMEDEL: TRUMP TRAPPAR UPP OPIATKAMPEN

Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 2021-03-04 · Opiant Pharmaceuticals has received 284 “underperform” votes. (Add your “underperform” vote.) Community Sentiment. Opiant Pharmaceuticals has received 52.11% “underperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Q4 2020 Earnings Conference Call March 4, 2021 4:30 PM ET Company Participants.

20180629 Nordea Markets - Saniona

It is engaged in developing opioid antagonist treatments for substance use, addictive and eating disorders. Opiant Opiant Pharmaceuticals Inc NASDAQ Updated Apr 9, 2021 8:18 PM. OPNT 11.06 0.30 (2.79%). Post-Market 0.56 (5.06%) At OPIANT BIOTECH LLP, Quality Assurance (QA) and Quality Control (QC) are two distinct processes that ensure our credibility. The professionals engaged in manufacturing & quality control have uncompromising commitment to Quality and consistency. SANTA MONICA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the fourth quarter and year ended December 31, 2020, after the financial markets close on Thursday March 4, 2021. Opiant Pharmaceuticals, Inc. operates as a specialty pharmaceutical company.

It is engaged in developing opioid antagonist treatments for substance use, addictive and eating disorders. Opiant Pharmaceuticals Inc., formerly known as Lightlake Therapeutics, Inc., is based in New York. Source: Opiant May Investor Presentation. Opiant has a sub-royalty agreement with SWK whereby they pass on 10% of the gross royalty they receive. They made the agreement with SWK in December 2016 in return for upfront cash.